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for the diagnosis of cirrhosis: A Pyrrhic victory?qWe appreciated the paper by Castera et al., compar-
ing ultrasonographic transient elastometry (TE) and
blood tests for the non-invasive diagnosis of cirrhosis
[1]. The authors should be commended for their use of
the intention-to-diagnose principle according to
STARD recommendations. However, this paper de-
serves several comments.
Blood tests were not favoured for several reasons.
First, common blood tests were used, but not the best
performing tests according to direct comparisons per-
formed in a large series [2]. Second, the prevalence of cir-
rhosis was higher (23%) than in a reference population
including about 33,000 liver biopsies (12%) [3]. Thus,
the AUROC of TE was higher (0.96) than that mea-
sured in a recent meta-analysis (0.94) [4], whereas the
AUROC of Fibrotest was lower (0.82) than that ob-
served in a meta-analysis (0.90) [5] and in a large series
(0.88) [2]. Third, blood tests are usually constructed to
diagnose signiﬁcant ﬁbrosis (i.e. Metavir FP 2). This
diagnostic target calls upon speciﬁc cut-oﬀs and speciﬁc
coeﬃcients for the markers included in the regression
score provided by binary logistic regression. When one
of the best performing blood tests for signiﬁcant ﬁbrosis,
like FibroMeter, is used for cirrhosis, its AUROC is
0.907 [2]. This can be increased to 0.919 by speciﬁcally
designing the test for cirrhosis (the same markers are in-
cluded but with diﬀerent coeﬃcients than those used for
signiﬁcant ﬁbrosis). This was responsible for a signiﬁ-
cant increase in the rate of correctly classiﬁed patients,
from 90.9% to 93.0% (p = 0.005) [2]. Based on personal
data and those provided by Castera et al., the diﬀerence
between the AUROC of TE – 0.96 (95% CI: 0.93–0.98) –
and FibroMeter speciﬁc for cirrhosis – 0.92 (0.89–0.95) –
is signiﬁcant (p = 0.04). However, if we consider the TE
AUROC provided by a meta-analysis – 0.94 (0.93–0.95)
[4] – the diﬀerence is not signiﬁcant (p = 0.25). More-
over, the rate of misclassiﬁed patients by TE was 8%
in the Castera paper vs 7.0% with FibroMeter speciﬁc
for cirrhosis [2].
The authors stated, ‘‘Overall, the percentage of cor-
rectly classiﬁed patients in whom liver biopsy could have
been avoided was 90%”. However, the authors did not
indicate how they calculated this ﬁgure. By using 95%
predictive values, the rate of avoided liver biopsy was
91.9% with FibroMeter speciﬁc for cirrhosis [6].
The authors also stated, ‘‘These results suggest that,
given the high accuracy of TE alone, combining TE with
serum indexes does not increase diagnostic accuracy forO. have stock ownership in BioLiveScale Inc. that has a
roMeters from Angers University.cirrhosis”. We recently observed that the combination of
a good performing blood test with TE could signiﬁ-
cantly decrease the rate of required liver biopsy, as
determined by predictive values.
Finally, by quoting a relatively old -1998- reference,
the authors suggested that the ‘‘reproducibility of mea-
surement of some parameters, such as, for instance
AST levels or platelet count, is questionable”, whereas
‘‘TE has been shown to be a highly reproducible and
operator-independent technique”. In fact, recent data
have indicated excellent interlaboratory reproducibility
for platelets and AST [7]. Other recent works have indi-
cated that the interobserver reproducibility of TE is
excellent for cirrhosis but not for the most frequent val-
ues of liver stiﬀness, and that operator expertise could
inﬂuence certain characteristics of TE [8]. Therefore,
the overall reproducibility is lower for TE than for
blood tests.
We conclude that the comparative study of Castera
et al. is rather a Pyrrhic victory. TE is an excellent
diagnostic tool for cirrhosis, but blood tests used as
comparator should be adequately quoted. We think
that TE combined with a blood test is a well-adapted
strategy in hepatology units, whereas a blood test,
combining two diagnostic targets – signiﬁcant ﬁbrosis
and cirrhosis – is convenient for other medical actors.
This strategy has been practised in our area since
April 2004.
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To the Editor:
Weunderstand the enthusiasm of Cale`s et al. [1] for the
test they have developed. However, we decided to com-
pare transient elastography (TE) with better validated
scores, i.e., APRI and Fibrotest [2,3], as well as cheaper
and routinely used laboratory tests (prothrombin index,
platelet count andAST/ALT ratio). Although the perfor-
mance of the Fibrometer appears to be very good in the
hands of its inventors, this score as been poorly evaluated
externally and is not yet widely used. As far as the diag-
nostic target is concerned, the cut-oﬀs used were those
recommended for cirrhosis by the manufacturer (Fibro-
test) or the authors (APRI andLok index).We alsowould
like to remind readers that the 90% of patients in whom
liver biopsy could have been avoided is the number of cor-
rectly classiﬁed patients (267 out of 298 [4]) using TE
(cut-oﬀ 12.5 kPa) in intention-to-diagnose analysis.
Cales’s discussion of our data is challenging, but their
statements are purely speculative and refer to a diﬀerent
patient population. Finally, we fully agree that combining
twounrelatedmethods such asTEand ablood test consis-
tently improves diagnostic accuracy, as we suggested for
the ﬁrst time in 2005 [5]. However, given the high perfor-
mance of TE for the diagnosis of cirrhosis, our strategy
seems more cost-eﬀective in clinical practice [6].
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